Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease
Syndecan-1 levels were higher in patients with Behçet's disease compared to controls, and increased syndecan-1 may slow the progression of subclinical atherosclerosis. This study is a preliminary investigation. Further detailed studies are needed. Cite this article as: Kadıyoran C, Diydem Yılmaz P, Hakan Göktepe M, et al. Syndecan-1 as a biomarker for cardiovascular risk in patients with Behçet's disease. Arch Rheumatol. 2025;40(4):435-442.
Authors
- Erkan Cüre (ORCID: https://orcid.org/0000-0001-7807-135X)
- Mustafa Oğul (ORCID: https://orcid.org/0000-0002-8044-7616)
- Adem KÜÇÜK (ORCID: https://orcid.org/0000-0003-2771-6191)
- Cengiz Kadıyoran (ORCID: https://orcid.org/0000-0002-7173-3530)
- Faik Özdengül (ORCID: https://orcid.org/0000-0001-9670-0789)
- Pınar Diydem Yılmaz (ORCID: https://orcid.org/0000-0002-8519-5382)
- Mevlüt Hakan Göktepe (ORCID: https://orcid.org/0000-0003-1711-5157)
Institutions
- Konya Numune Hastanesi (TR)
- Necmettin Erbakan University (TR)
- Istinye University (TR)
Publication Details
- Journal
- Archives of Rheumatology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.5152/archrheumatol.2025.11178
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00